Neurofibromatosis type 1 (NF1) is a common disorder that arises secondary to mutations in the tumor suppressor gene NF1. Glomus tumors are small, benign but painful tumors that originate from the glomus body, a thermoregulatory shunt concentrated in the fingers and toes. We report 11 individuals with NF1 who harbored 20 glomus tumors of the fingers and 1 in the toe; 5 individuals had multiple glomus tumors. We hypothesized that biallelic inactivation of NF1 underlies the pathogenesis of these tumors. In 12 NF1-associated glomus tumors, we used cell culture and laser capture microdissection to isolate DNA. We also analyzed two sporadic (not NF1-associated) glomus tumors. Genetic analysis showed germ line and somatic NF1 mutations in seven tumors. RAS mitogenactivated protein kinase hyperactivation was observed in cultured NF1 À/À glomus cells, reflecting a lack of inhibition of the pathway by functional neurofibromin, the protein product of NF1. No abnormalities in NF1 or RAS mitogen-activated protein kinase activation were found in sporadic glomus tumors. By comparative genomic hybridization, we observed amplification of the 3 ¶-end of CRTAC1 and a deletion of the 5 ¶-end of WASF1 in two NF1-associated glomus tumors. For the first time, we show that loss of neurofibromin function is crucial in the pathogenesis of glomus tumors in NF1. Glomus tumors of the fingers or toes should be considered as part of the tumor spectrum of NF1.
Introduction
Neurofibromatosis type 1 (NF1) is a common (1/3,000), autosomal dominant disorder that arises secondary to mutations in the tumor suppressor gene NF1 (1). The protein product of NF1, neurofibromin, regulates RAS through its GTPase activating protein-related domain (2) . Individuals with NF1 are at an increased risk for a variety of benign and malignant tumors. Biallelic inactivation (a ''second hit''; ref.
3) of NF1 due to loss of heterozygosity (LOH) or somatic mutation is pathogenic in a variety of NF1-associated tumors (4) .
Glomus tumors are benign neoplasms that arise from the glomus body, a specialized thermoregulatory shunt concentrated in the fingers and toes (5) . Glomus tumors in the fingers or toes are distinct from adrenal and extra-adrenal paragangliomas, also called ''glomus tumors'' (6) . The glomus body is a highly innervated structure containing an afferent arteriole, an anastomotic SuquetHoyer canal, and an efferent venule. The canal is surrounded by concentric layers of contractile a-smooth muscle actin (aSMA)-positive glomus cells. Heat-induced contraction of the glomus body causes closure of the arteriovenous anastomosis and forces blood flow through the capillary network of the distal phalanx, causing heat loss (7) . Cold temperatures prompt relaxation of the glomus body, opening the anastomosis and conserving body heat.
Sporadic glomus tumors of the fingers are solitary and predominantly affect middle-aged women (5, 8, 9) . Affected individuals present with a triad of severe paroxysmal pain, cold intolerance, and localized tenderness. The first association of NF1 and glomus tumors (at any location) was published in 1938 (10) . To date, there are eight published cases of an NF1 association and glomus tumors of the fingers or toes in the English-language literature (11) (12) (13) (14) (15) . There were no examples of multifocal glomus tumors in two large retrospective reviews of 86 sporadic cases (8, 9) . However, of the eight individuals with NF1 and glomus tumors of the fingers or toes, seven harbored multiple tumors (11, 12, 14, 15) , suggesting an association.
We hypothesized that biallelic inactivation of NF1 is pathogenic in NF1-associated glomus tumors (14) . In this report, we searched for somatic NF1 mutations, loss of neurofibromin function, and dysregulation of the RAS mitogen-activated protein kinase (MAPK) pathway in glomus cells in NF1-associated and sporadic glomus tumors. We also investigated genome copy number changes using comparative genomic hybridization (CGH).
cell cultures. The three glomus tumors from NF1-G10 were fixed in HistoChoice (an alcohol-based fixative; Sigma) prior to laser capture microdissection (LCM). Primary glomus cell cultures were also established from two tumors from two individuals without NF1. Skin fibroblast culture from a normal control was also available.
Cell Culture
Surgically excised glomus tumors were treated overnight with collagenase (160 units/mL) and dispase (0.8 units/mL) at 37jC. Glomus cells were grown to confluency in DMEM/F12 + 10% fetal bovine serum + penicillin + streptomycin and harvested.
Immunocytochemistry
For immunofluorescent staining, cells cultured from glomus tumors were fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100, and blocked with 10% fetal bovine serum. The cells were washed with PBS with 1% fetal bovine serum and incubated with mouse anti-aSMA antibody (1:400; Sigma). Wash with PBS with 1% fetal bovine serum was followed by incubation with a fluorescent goat anti-mouse antibody (AlexaFluor 488, Invitrogen). Slides were mounted with mounting medium (Vectashield, Vector Laboratories) and cell nuclei were visualized with 4 ¶,6-diamidino-2-phenylindole.
DNA Isolation from Paraffin-Embedded Tissue
Eight-micron sections from the three glomus tumors from patient NF1-G10 were mounted onto PEN membrane slides (Zeiss) and stained with H&E. Lesional tumor cells were microdissected from surrounding stroma and vasculature with either the PALM II (Zeiss) or the PixCell II (Molecular Devices) LCM systems. The tissue fragments were digested in proteinase K and DNA extracted according to the instructions of the manufacturer (Picopure DNA extraction kit, Molecular Devices). For single nucleotide polymorphism-CGH (SNP-CGH), LCM material was resuspended in buffer containing 0.5 mol/L of Tris-HCl (pH 9.0), 0.5% SDS, and 5 mmol/L of EDTA. Proteinase K (Invitrogen) at 400 Ag/AL was added, and samples were incubated at 55jC for 16 h. Samples were extracted with phenol/chloroform and DNA was precipitated. The DNA concentration was quantified using Picogreen (Invitrogen) and/or by spectrophotometer (NanoDrop ND-1000, Thermo Scientific) analysis at 260 nm.
Whole Genome Amplification
The DNA extracted from tumor nos. 1, 2, and 3 from patient NF1-G10 were subjected to whole genome amplification by either multiple displacement amplification with the Repli-G kit (Qiagen) or a PCR-based method with the GenomePlex kit (Sigma). The instructions of the manufacturer were followed with appropriate controls.
Germ Line and Somatic NF1 Mutation Detection and LOH Analysis
Germ line mutation screening of NF1 was performed on cDNA from puromycin-treated lymphocytes (16) . Detected mutations were confirmed on genomic DNA. NF1 somatic mutation analysis was performed using the same technique on cell cultures derived from glomus tumors. Somatic NF1 mutation analysis was performed on whole genome amplification DNA from tumor nos. 1, 2, and 3 subjected to LCM from participant NF1-G10 as per published methods (17, 18) . Somatic mutations of NF1 were confirmed on nonamplified tumor genomic DNA. Multiplex liganddependent probe amplification was used to assay exonic deletions (19) . LOH analysis on DNA from cell cultures from glomus tumors (tumor no. 1, NF1-G4; tumor no. 1, NF1-G6; tumor no. 1, NF1-G7; tumor no. 1, NF1-G9) was performed by genotyping microsatellite markers telomeric to 
Biallelic Assignment of Somatic and Germ Line NF1 Mutations
Germ line and somatic NF1 mutations may occur on the same or different alleles. In non-whole genome amplification tumor DNA from NF1-G10, SNPs rs2269855 and rs7350946 were coamplified by PCR with NF1 somatic mutation nos. 2 and 3; in germ line DNA from NF1-G10, SNP rs2525565 was coamplified with the NF1 germ line mutation ( Table 1 ). The PCR products were subcloned into the TOPO-TA vector (Invitrogen), and transformed into DH5a cells, harvested, and sequenced. To create NF1 haplotypes, nine informative NF1 SNPs were genotyped in participant NF1-G10 and family members (Fig. 1) . Assignment of status (wild-type or NF1 mutation) to the haplotypes was then determined by segregation analysis within the family.
Bisulfite Modification and Human Androgen Receptor Assay Methylation-Specific PCR to Assess the Clonality of Glomus Tumors
We used the human androgen receptor assay methylation-specific PCR (25) , with minor modifications (Supplemental Table S1 ) to determine the clonality of the three tumors from NF1-G10 (26) . Bisulfite modification was performed using the Epitect bisulfite modification kit (Qiagen) according to the instructions of the manufacturer. Bisulfite-modified DNA was used in the human androgen receptor assay methylationspecific PCR assay using Amplitaq Gold 2Â PCR mastermix (Applied Biosystems) in a thermal cycler (MJ Research). PCR products were analyzed with an ABI 3100 Genetic Analyzer (Applied Biosystems) using GeneMapper software (version 3.1, Applied Biosystems). Germ line DNA from NF1-G10 was used as a polyclonal control. As a monomorphic control, germ line DNA from three females with oculofaciocardiodental syndrome was used (27) .
RAS-MAPK Pathway Analysis of Glomus Cells
Cell culture of glomus tumors [NF1-associated glomus tumor-derived glomus cells, NF1-associated glomus tumor-derived fibroblasts, sporadic (non-NF1) glomus tumor-derived glomus cells, and control fibroblasts (skin fibroblasts from an individual not affected with NF1)] were grown to confluence, starved overnight in serum-free medium and stimulated with acidic fibroblast growth factor (aFGF, 10 ng/mL; Sigma) for 5, 15, 30, 45, and 60 min. Cell lysates were analyzed by Western blot. DNA was also extracted from the NF1-associated glomus tumor-derived glomus cells to confirm the somatic and germ line NF1 mutations. Antibodies used for immunoblotting included anti-phosphorylated MAPK kinase 1 and 2 (MEK1/2; Cell Signaling Technology), anti-MEK1/2 (Santa Cruz Biotechnology), anti-phosphorylated extracellular signal-regulated kinase 1 and 2 (ERK1/2; Cell Signaling), anti-ERK1/2 (Cell Signaling), and anti-h-actin (Sigma). Quantitative analysis of Western blot images was performed using Scion software (Scion Corp.). Experiments were performed in triplicate. Statistical significance was determined by multivariate repeated measures ANOVA.
CGH
Illumina HumanHap550 SNP-CGH. Unamplified DNA (f500 ng) microdissected from both glomus tumor nos. 1 and 3 and germ line DNA from NF1-G10 was hybridized to Illumina HumanHap550 Genotyping BeadChips (Illumina). Data was analyzed using Illumina BeadStudio software version 3.1 with genotyping module version 3.2.23. To assess LOH and copy number changes, we used the ''LOH score'' and ''CNV partition'' algorithms. The recommended thresholds for a significant LOH score is >5 and a confidence score of 100 (''DNA Copy Number Analysis Algorithms, '' Illumina publication no. 970-2007-008, March 12, 2008) . Genomic coordinates for all SNPs were derived from dbSNP build 129.
We also identified discordant loci by comparing SNP genotypes of tumor and corresponding germ line DNA at each SNP locus. For those SNPs with apparent LOH, we then identified the nearest centromeric and telomeric heterozygous (informative) SNPs to establish an interval with putative LOH.
Agilent oligo Array-CGH. Array-CGH using the Agilent Human Genome Microarray kit 244A (Agilent Technologies) was performed on tumor DNA from primary glomus tumor cell cultures from participants NF1-G1 (tumor no. 1), NF1-G3 (tumor no. 3), NF1-G8 (tumor no. 1), non-NF1-G1, and non-NF1-G2. The presence of a somatic NF1 mutation was confirmed in each culture of NF1-associated glomus tumor-derived glomus cells tested by array-CGH. Matching genomic DNA was available for the three tumors from individuals with NF1. For the tumors from individuals not affected with NF1, we used gender-matched genomic DNA from a healthy control. Digestion, labeling, and hybridization were performed according to the instructions of the manufacturer ('' Agilent Oligonucleotide Array-Based CGH for Genomic DNA Analysis'' protocol, v4.0, June 2006). Microarrays were scanned by the Genepix 4000B scanner (Axon Instruments, Molecular Devices) and analyzed by the Agilent Feature Extraction software (v9.5.1). Results were visualized by Agilent CGH Analytics software (v3.5.14). Quantitative PCR at the CRTAC1, GUCY1A2, and WASF1 Loci
Three loci (CRTAC1, GUCY1A2, and WASF1) with SNP-CGH evidence of copy number changes were evaluated with custom TaqMan PCR assays (Applied Biosystems) according to the instructions of the manufacturer. Unamplified genomic DNA (1 ng) isolated by LCM from glomus tumor nos. 1 and 3 and germ line DNA (1 ng) were used in the quantitative PCR reactions. All reactions were performed in triplicate in a 7900HT Fast Real-time PCR instrument (Applied Biosystems). Relative amounts of DNA in each sample/ locus were calculated using the standard ''double delta'' Ct method and expressed as a percentage of the DNA in the germ line sample. Primers are listed in Supplemental Table S1. RNase P RNA component H (RPPH1) was used as a normalizing control. For each gene, a standard t test was used to test for the significance of differences in relative DNA amount between germ line and tumor samples.
Results

Clinical Characterization of NF1-Associated Glomus Tumors
We evaluated 11 individuals (three males and eight females; ages, 11-59 years; mean age excluding the child, 40 years) with signs and symptoms of NF1 with 21 pathologically confirmed glomus tumors of the fingers and toes (Table 1) . One individual (NF1-G6) was diagnosed with mosaic NF1 (previously reported patient SNF1-1; ref. 28 ). The remaining 10 individuals fulfilled the consensus criteria for the diagnosis of NF1. The clinical data of two of these 10 individuals have been previously reported (NF1-G2 as ''case 2'' and NF1-G3 as ''case 1''; ref. 14) . A pathogenic germ line mutation in Figure 1 . Pedigree of NF1-G10 with phased 11 SNP NF1 haplotypes spanning f203 kb (5 ¶ end at top, 3 ¶ end at bottom). SNP alleles subcloned with germ line and somatic mutations are in boldface. The maternal haplotype harboring the NF1 germ line mutation (c.6789_6792 del TTAC, subcloned with SNP rs2525565; in black ) cosegregates with the NF1 affectation status in the two affected sons (Son 1 and Son 2 ). The maternal haplotype harboring the two somatic NF1 mutations (light gray ) is transmitted to the unaffected son (Son 3 ).
NF1 was identified in all individuals, with the exception of N1-G6 (mosaic NF1), for whom the mosaic NF1 mutation was found in neurofibroma-derived Schwann cells (28) .
Five of the 11 individuals harbored multiple glomus tumors. Twenty of the 21 glomus tumors were located in the fingertips, with the exception of NF1-G9, whose tumor was located in the right hallux. Ten tumors were located in the right hand, and 10 in the left hand. The aggregate distribution of tumors was similar for both hands: F1/thumb (5%), F2 (5%), F3 (25%), F4 (50%), and F5 (15%).
NF1-Associated Glomus Tumors Show Typical Glomus Tumor Morphology
Histologic examination of all 21 tumors revealed small vessels surrounded by uniform cuboidal cells without cytologic atypia, necrosis, or increased mitotic activity (Fig. 2A) . Immunostaining with aSMA showed uniformly positive cytoplasmic staining in the tumor cells (Fig. 2B ).
NF1-Associated Glomus Tumors Arise Secondary to Somatic NF1 Mutations in ASMA-Positive Glomus Cells
We used two strategies to collect DNA from small glomus tumors, (a) fresh tissue culture to derive glomus cells and fibroblasts (nine tumors) and (b) LCM of paraffin-embedded tissue (three tumors).
In the cultured tumors, the glomus cells were aSMA-positive (Fig. 2B) . In addition to the germ line mutations, five somatic mutations were identified in five of the nine tumors (Table 1) . No NF1 mutations were detected in glomus cells or fibroblasts from two sporadic glomus tumors. In the three tumors subject to LCM, two different somatic mutations were identified in two tumors (Table 1) in addition to the germ line mutation. All seven somatic mutations are predicted to inactivate NF1. Using segregation analysis of NF1 SNP haplotypes harboring the NF1 germ line and somatic mutations in the pedigree of NF1-G10, we proved that the germ line and somatic mutations arose on separate copies of chromosome 17 (Fig. 1) .
NF1-Associated Glomus Tumors are Monoclonal by Human Androgen Receptor Assay MethylationSpecific PCR
Because NF1-associated glomus tumors arise from biallelic inactivation of NF1, we reasoned that they should harbor evidence of a monoclonal expansion from a single cell. In three different glomus tumors from three fingers of one female (NF1-G10), a single allele was detected using the methylated-and unmethylatedspecific primer pairs (Supplemental Fig. S1 ), consistent with monoclonal tumor expansion.
Biallelic Inactivation of NF1 in NF1-Associated Tumor-Derived Glomus Cells Increased Activation of the RAS-MAPK Pathway Compared with Other NF1-Associated Cells and Control Skin Fibroblasts
Because biallelic inactivation of NF1 was observed in NF1-associated tumor-derived glomus (aSMA positive) cells, we reasoned that MAPK pathway activity should be elevated when compared with NF1-associated glomus tumor-derived (aSMA negative) fibroblasts, sporadic glomus tumor-derived glomus (aSMA positive) cells, and control skin fibroblasts.
Consistent with the predicted effects of NF1 biallelic inactivation, we observed significantly higher MEK1/2 phosphorylation ratios in NF1-associated glomus tumor-derived glomus cells when compared with the three cell types described above at 5, 15, and 30 minutes after stimulation with aFGF (Fig. 3) . The NF1-associated glomus tumor-derived fibroblasts showed less MEK1/2 activation in comparison to the NF1-associated glomus tumor-derived glomus cells but a higher activation at 5 and 15 minutes when compared with sporadic glomus tumor-derived glomus cells and control skin fibroblasts.
Similarly, we observed increased activation of ERK1/2 phosphorylation after stimulation with aFGF (Fig. 3) . The maximum pERK/ERK ratio was detected in the NF1-associated glomus tumor-derived glomus cells 15 minutes after stimulation; the pERK/ERK ratios did not return to prestimulation levels even 60 minutes after stimulation. The NF1-associated glomus tumorderived fibroblasts, sporadic glomus tumor-derived glomus cells, and skin fibroblasts showed a similar but significantly lower increase in pERK/ERK ratios after stimulation with aFGF at all time points; 30 minutes after stimulation, the pERK/ERK ratio in these three cell types returned to prestimulation levels. Taken together, these data are consistent with the effects of NF1 biallelic inactivation on the MAPK pathway in NF1-associated glomus tumor-derived glomus cells (29, 30) .
Copy Number Changes at the CRTAC1 and WASF1 loci Illumina HumanHap550 SNP-CGH and quantitative PCR with microdissected tumor DNA. Supplemental Table S2 lists loci with evidence of copy number alterations in glomus tumor nos. 1 and 3 ( from NF1-G10), but not in germ line DNA. All copy number variants (CNVs) detected were located at least 20 kb (often substantially more) from a known gene, except for four that were found to be within CRTAC1 (glomus tumor nos. 1 and 3), WDR78, GUCY1A2, and VPS13C (glomus tumor no. 3 only).
Because the LOH score and CNV partition score are insensitive to the detection of copy number changes at a single SNP, we sought discrepancies in SNP genotypes between tumor and germ line samples. One SNP (rs4945851, intron 1 of WASF1) was discrepant (Fig. 4) . There was no evidence of a copy number change at the two closest flanking SNPs (rs6568634 and rs7761436), thus delimiting the size of the WASF1 putative deletion to f10 kb.
Due to severe limitations of the availability of tumor DNA, we performed quantitative PCR on CRTAC1, WASF1, and GUCY1A2. In both CRTAC1 and WASF1, we observed copy number changes consistent with those observed in the SNP-CGH data (Fig. 5 ). We were unable to confirm the homozygous deletion in tumor no. 3 of the GUCY1A2 locus.
Agilent oligonucleotide array-CGH with DNA from the cell culture. Oligonucleotide array-CGH analysis did not show copy number changes in cultured cells from the glomus tumors with proven NF1 inactivation (data not shown), more specifically, the loci identified by the Illumina platform on DNA extracted from paraffin-embedded tissues were normal. Similarly, the two glomus tumors from individuals not affected with NF1 and the non-NF1 control fibroblasts did not show any copy number alterations.
Discussion
In this report, we present the first genetic and molecular proof of an association of glomus tumors of the fingers and toes with NF1. The mean age of adult participants in our study (40 years ) is comparable to that of the sporadic glomus tumor population (9) . However, one participant in our study (NF1-G7) was only 11 years old. We also observed multiple glomus tumors in 45% of our participants, a feature not observed in sporadic glomus tumors. In tumor predisposition syndromes such as NF1, an early age of onset and the presence of multifocal tumors are evidence of an association.
Glomus tumors are small (typically <5 mm). We used two techniques to obtain tumor DNA. We identified both germ line and somatic mutations in NF1 in six tumors; in a seventh tumor, we found an NF1 germ line mutation plus LOH (1/7 = 14%; 95% A, cell extracts immunoblotted with the indicated antibodies. B, ratios of pMEK/MEK and pERK/ERK. All ratios were normalized to the ratio of the specific cell type before stimulation. Points, mean; bars, SD. Average pMEK/MEK and pERK/ERK ratios of the four cell types were significantly different (P V 10 confidence interval, 0.003-0.578). The rate of LOH we detected in glomus tumors is not significantly different from the expected 25% observed in neurofibromas (binomial distribution; ref. 31) due to our modest sample size. In two tumors, we showed that the wildtype chromosome harbored the somatic mutation (the ''second hit'' of Knudson's two-hit hypothesis). Biallelic inactivation of NF1 is a common pathogenic mechanism of NF1-associated tumors. In four tumors from two individuals, four different somatic NF1 mutations were identified, suggesting that the multifocal NF1-associated glomus tumors arise from independent events. Presumably, NF1-nullizygosity arises in glomus cells secondary to mitotic DNA replication errors in NF1; this matters because glomus cells rely on neurofibromin-dependent RAS-MAPK-related growth factor cascades.
We also sought evidence of the functional consequences of the inactivation of NF1. Biallelic inactivation of NF1 in NF1-associated glomus tumor-derived glomus cells results in an increased activation of the MAPK pathway, as observed in other tumor cells with biallelic inactivation of NF1 (29, 30) . Biochemical analysis of NF1-associated tumor-derived glomus cells (with germ line and somatic NF1 mutations) showed stronger and longer activation of the MAPK pathway after stimulation with aFGF when compared with NF1-associated tumor-derived fibroblasts (with a germ line NF1 mutation only), sporadic tumor-derived glomus cells (no NF1 mutations), and normal skin fibroblasts (no NF1 mutations). In three (of three) glomus tumors from three different fingertips from a single female, X-inactivation as detected by the human androgen receptor assay methylation-specific PCR assay was consistent with monoclonal expansion of the glomus tumors. Such an expansion is compatible with the consequences of biallelic inactivation of a tumor suppressor gene (such as NF1) in a single cell (32) .
We performed a genome-wide search for copy number changes in both cultured and paraffin-embedded tumor cells. In participant NF1-G10 tumor no. 1 (no somatic NF1 mutation identified) and tumor no. 3 (biallelic NF1 inactivation), quantitative PCR was consistent with a partial deletion of a portion of the 5 ¶-untranslated region of WASF1 (Fig. 5) . Interestingly, WASF1 forms a bidirectional gene pair with the 5 ¶ CDC40. The bidirectional promoter of WASF1 and CDC40 is located within the putative deletions of both tumors from NF1-G10. Deletion of the bidirectional promoter may plausibly affect the expression of both WASF1 and CDC40. There is significant overrepresentation of bidirectional promoters associated with cancer-related genes (33); their role in benign tumors is unknown. WASF1 is down-regulated in ovarian cancer (34) . There are no reported mutations in human CDC40, an orthologue of yeast CDC40, which is a controller of cell cycle arrest (35) . Both WASF1 and CDC40 are candidates for further investigation in glomus tumors.
A f50 kb amplification within CRTAC1 was also observed in both glomus tumors from NF1-G10. CRTAC1 encodes human cartilage acidic protein 1 and is useful in distinguishing chondrocyte-like, osteoblast-like, and mesenchymal stem cells in culture (36) . The PRINTS database 14 predicts a COOH-terminal antifreeze type I domain in CRTAC1 . Antifreeze proteins were identified in polar fish as an adaptation to survive in hypothermic conditions preventing cell damage (37) . In prolonged subzero cryopreservation, antifreeze proteins protect the heart from freezing, improve survival, and reduce apoptosis (38) . Antifreeze domains are rare in the human genome. Their role in the pathogenesis of glomus tumors, derived from cold-responsive contractile glomus cells, is unknown.
Analysis of the cultured NF1 tumor-derived glomus cells by array-CGH did not show copy number alterations. It is possible that the cell culture procedure selected for glomus cells without copy number alterations.
Lastly, many neural crest-derived cell types are involved in NF1 (39) . Three observations from our data support a neural crest origin for glomus cells and their cognate tumors. First, glomus cells are aSMA-positive; progenitor cells cultured from rat sciatic nerve suggest that neural crest stem cells generate aSMA-positive myofibroblasts (40) . Second, the five NF1-associated tumor-derived cell cultures with a somatic NF1 mutation showed that only aSMApositive glomus cells, and not tumor-derived fibroblasts, harbored somatic and germ line NF1 mutations. Third, the unusual phenotype of participant NF1-G6 is consistent with somatic mosaicism mainly confined to cells of neural crest origin (28) . She had a mosaic NF1 phenotype, confirmed by molecular analysis: she presented with a glomus tumor, neurofibromas on the back and an intestinal ganglioneuroma but no freckling, learning disabilities, Lisch nodules, or localized hyperpigmentation. Mosaicism in NF1 arises from a postzygotic mutation of NF1 (41). In the case of NF1-G6, that mutation event likely occurred in the neural crest or a neural crestderived cell, because both Schwann cells (neurofibroma) and intestinal ganglion cells (ganglioneuroma) are of neural crest origin. Accordingly, we hypothesize that glomus cells (glomus tumor) arise from myofibroblasts derived from neural crest stem cells.
In summary, we show that glomus tumors in NF1 arise secondary to biallelic inactivation of the tumor suppressor gene NF1 in aSMA-positive glomus cells. We observed that NF1-inactivated glomus cells show increased MAPK signaling. Taken together, these data prove that glomus tumors of the fingers are an integral part of the tumor spectrum of NF1. We hope that an increased awareness of these tumors will improve their early diagnosis and treatment in individuals with NF1.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
